1887

Abstract

The immunogenicity of specific varicella-zoster virus (VZV) proteins, with emphasis upon cell-mediated immune responses, was evaluated by immunizing strain 2 guinea-pigs with vaccinia virus recombinants that express gpI (vac-gpI), gpIV (vac-gpIV) and gpV (vac-gpV) or the IE-62 protein (vac-IE-62). Vac-gpI elicited the highest initial mean T cell proliferation response [stimulation index (S.I.) 3.8 ± 0.9 ] whereas inoculation with vac-gpV produced the lowest primary T cell response (S.I. 2.5 ± 1.1 ). T cell proliferation was detected for a shorter period after immunization with vac-gpV compared to vac-gpI, vac-gpIV or vac-IE-62. A comparison of the immunogenicity of vac-gpI and vac-IE-62 with the same proteins prepared by immunoaffinity purification showed that immunization with these proteins in either form elicited virus-specific IgG antibodies and T cell recognition. The presence or absence of IgG antibodies to the IE-62 protein was used to assess protection against challenge with guinea-pig cell-adapted infectious VZV in animals that had been inoculated with vac-gpI, vac-gpIV or vac-gpV. Immunization with vac-gpI and vac-gpIV restricted VZV replication but all animals given vac-gpV developed antibodies to IE-62 after challenge with infectious VZV. Priming of the T lymphocyte response was observed in all animals immunized with VZV-vaccinia virus recombinants after subsequent exposure to infectious VZV. These experiments with VZV vac-gpI, vac-gpIV and vac-gpV in guinea-pigs suggest variability in the capacity of herpesviral glycoproteins to elicit cell-mediated immunity . Induction of virus-specific immunity using IE-62 means that this major tegument protein of VZV could be a useful component for vaccine development.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-73-4-811
1992-04-01
2022-10-07
Loading full text...

Full text loading...

/deliver/fulltext/jgv/73/4/JV0730040811.html?itemId=/content/journal/jgv/10.1099/0022-1317-73-4-811&mimeType=html&fmt=ahah

References

  1. Arvin A. M., Koropchak C. M., Wittek A. E. 1983; Immunologic evidence of reinfection with varicella-zoster virus. Journal of Infectious Diseases 148:200–205
    [Google Scholar]
  2. Arvin A. M., Koropchak C. M., Williams B. R. G., Grumet F. C., Foung S. K. 1986a; Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. Journal of Infectious Diseases 154:422–429
    [Google Scholar]
  3. Arvin A. M., Kinney-Thomas E., Shriver K., Grose C., Koropchak C. M., Scranton E., Wittek A. E., Diaz P. S. 1986b; Immunity to varicella-zoster viral glycoproteins, gpI (90/58) and gpIII (gp 118) and to a nonglycosylated protein, p170. Journal of Immunology 137:1346–1351
    [Google Scholar]
  4. Arvin A. M., Solem S. M., Koropchak C. M., Kinney-Thomas E., Paryani S. G. 1987; Humoral and cellular immunity to varicella-zoster virus glycoprotein, gpI, and to a non-glycosylated protein, p170, in the strain 2 guinea-pig. Journal of General Virology 68:2449–2454
    [Google Scholar]
  5. Arvin A. M., Sharp M., Smith S., Koropchak C. M., Diaz P. S., Kinchington P., Ruyechan W., Hay J. 1991; Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T-lymphocytes of either CD4+ or CD8+ phenotype. Journal of Immunology 146:257–264
    [Google Scholar]
  6. Ayres J. P. 1971; Studies of the delta herpesvirus isolated from the patas monkey (Erythrocebus patas). Laboratory Animal Science 21:685–695
    [Google Scholar]
  7. Berman P. W., Gregory T., Crase D., Lasky L. A. 1985; Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 227:1490–1492
    [Google Scholar]
  8. Bernstein D. I., Stanberry L. R., Kappes J. C., Burke R. L., Meyers M. G. 1988; Antibody to herpes simplex virus (HSV) ICP-35 proteins after HSV challenge of animals immunized with HSV subunit vaccines. Journal of Infectious Diseases 157:1178–1186
    [Google Scholar]
  9. Blacklaws B. A., Krishna S., Minson A. C., Nash A. A. 1990; Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants. Virology 177:727–736
    [Google Scholar]
  10. Buller R. M. L., Smith G. L., Cremer K., Notkins A. L., Moss B. 1985; Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature, London 317:813–815
    [Google Scholar]
  11. Chakrabarti S., Brechling K., Moss B. 1985; Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Molecular and Cellular Biology 5:3403–3409
    [Google Scholar]
  12. Child S. J., Palumbo G., Buller M., Hruby D. E. 1990; Insertional inactivation of the vaccinia virus M1 subunit of ribonucleotide reductase results in in vivo attenuation of recombinant virions. Virology 174:625–629
    [Google Scholar]
  13. Cremer K. J., Mackett M., Wohlenberg C., Notkins A. L., Moss B. 1985; Vaccinia virus recombinant expressing herpes simplex virus type 1glycoprotein D prevents latent herpes in mice. Science 228:737–740
    [Google Scholar]
  14. Davison A. J., Scott J. E. 1986; The complete DNA sequence of varicella-zoster virus. Journal of General Virology 67:1759–1816
    [Google Scholar]
  15. Davison A. J., Waters D. J., Edson C. M. 1985; Identification of the products of a varicella-zoster virus glycoprotein gene. Journal of General Virology 66:2237–2242
    [Google Scholar]
  16. Diaz P. S., Smith S., Hunter E., Arvin A. M. 1988; Immunity to varicella-zoster virus antigen, glycoprotein I (gpI) and a nonglycosylated protein (p170): relation to the immunizing regimen of live attenuated varicella vaccine. Journal of Infectious Diseases 158:1245–1252
    [Google Scholar]
  17. Edmond B. J., Grose C., Brunell P. A. 1981; Varicella-zoster virus infection of diploid and chemically transformed guinea-pig embryo cells: factors influencing virus replication. Journal of General Virology 54:403–407
    [Google Scholar]
  18. Felsenfeld A. D., Schmidt N. J. 1979; Varicella-zoster virus immunizes patas monkeys against simian varicella-like disease. Journal of General Virology 42:171–178
    [Google Scholar]
  19. Friedrichs W. E., Grose C. 1984; Glycoprotein gp118 of varicella-zoster virus: purification by serial affinity chromatography. Journal of Virology 49:992–996
    [Google Scholar]
  20. Gelb L. 1990; Varicella zoster virus. In Virology 2nd edn., pp 2011–2054 Edited by Fields B. N., Knipe D. M. New York: Raven Press;
    [Google Scholar]
  21. Gönczöl E., Hudecz F., Ianacone J., Dietzschold B., Starr S., Plotkin S. A. 1986; Immune responses to the isolated human cytomegalovirus envelope proteins. Journal of Virology 58:661–664
    [Google Scholar]
  22. Grose C., Friedrichs W. E. 1982; Immunoprecipitable polypeptides specified by varicella zoster virus. Virology 118:86–95
    [Google Scholar]
  23. Hayward A. R., Burger R., Scheper R., Arvin A. M. 1991; Major histocompatibility complex restriction of T cell responses to varicella-zoster virus in guinea pigs. Journal of Virology 65:1491–1495
    [Google Scholar]
  24. Keller P. M., Neff B. J., Ellis R. W. 1984; Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes. Journal of Virology 52:293–297
    [Google Scholar]
  25. Kinchington P. R., Remenick J., Ostrove J. M., Straus S. E., Ruyechan W. T., Hay J. 1986; Putative glycoprotein gene of varicella-zoster virus with variable copy numbers of a 42-base pair repeat sequence has homology to herpes simplex virus glycoprotein C. Journal of Virology 59:660–668
    [Google Scholar]
  26. Kinchington P. R., Ling P., Pensiero M., Moss B., Ruyechan W. T., Hay J. 1990; The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). Journal of Virology 64:4540–4548
    [Google Scholar]
  27. Kinchington P. R., Hougland J. K., Arvin A. M., Ruyechan W. T., Hay J. 1991; Varicella zoster virus IE 62 protein is a major virion component. Journal of Virology (in press)
    [Google Scholar]
  28. Koropchak C. M., Solem S. M., Diaz P. S., Arvin A. M. 1989; Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. Journal of Virology 63:2392–2395
    [Google Scholar]
  29. Matsunaga Y., Yamanishi K., Takahashi M. 1982; Experimental infection and immune response of guinea pigs with varicellazoster virus. Infection and Immunity 37:407–412
    [Google Scholar]
  30. Meignier B., Jourdier T. M., Norrild B., Pereira L., Roizman B. 1987; Immunization of experimental animals with reconstituted mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. Journal of Infectious Diseases 155:921–930
    [Google Scholar]
  31. Mertz G. J., Peterman G., Ashley R., Jourden J. L., Salter D., Morrison L., McLean A., Corey L. 1984; Herpes simplex virus type 2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans. Journal of Infectious Diseases 150:242–249
    [Google Scholar]
  32. Moss B., Flexner C. 1987; Vaccinia virus expression vectors. Annual Review of Immunology 5:305–324
    [Google Scholar]
  33. Myers M. G., Stanberry L. R., Edmond B. J. 1985; Varicellazoster virus infection of strain 2 guinea pigs. Journal of Infectious Diseases 151:106–113
    [Google Scholar]
  34. Myers M. G., Duer H. L., Hausler C. K. 1980; Experimental varicella-zoster virus infection of guinea pigs. Journal of Infectious Diseases 142:414–420
    [Google Scholar]
  35. Myers M. G., Connelly B. L., Stanberry L. R. 1991; Varicella in hairless guinea pigs. Journal of Infectious Diseases 163:746–751
    [Google Scholar]
  36. Roberts P. L., Duncan B. E., Raybould T. J. G., Watson D. H. 1985; Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge. Journal of General Virology 66:1073–1083
    [Google Scholar]
  37. Sekulovich R. E., Ng P., Burke R. L. 1990; Immunization of guinea pigs with a vaccinia/VP16 recombinant virus elicits neutralizing antibody titers and protects against HSV-2 challenge. Abstracts, 15th International Herpesvirus Workshop p. 395
    [Google Scholar]
  38. Stanberry L. R., Bernstein D. L., Burke R. L., Pachl C., Myers M. 1987; Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. Journal of Infectious Diseases 155:914–920
    [Google Scholar]
  39. Vafai A., Wroblewska Z., Mahalingam R., Cabirac G., Wellish M., Cisco M., Gilden D. 1988; Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies. Journal of Virology 62:2544–2551
    [Google Scholar]
  40. Wachsman M., Aurelian L., Smith C. C., Lipinskas B. R., Perkus M. E., Paoletti E. 1987; Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. Journal of Infectious Diseases 155:1188–1197
    [Google Scholar]
  41. Weir J. P., Bennett M., Allen E. M., Elkins K. L., Martin S., Rouse B. T. 1989; Recombinant vaccinia virus expressing the herpes simplex type 1 glycoprotein C protects mice against herpes simplex virus challenge. Journal of General Virology 70:2587–2594
    [Google Scholar]
  42. Willey D. E., Cantin E. M., Hill L. R., Moss B., Notkins A. L., Openshaw H. 1988; Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection. Journal of Infectious Diseases 158:1382–1385
    [Google Scholar]
  43. Yao F., Courtney R. J. 1989; A major transcriptional regulatory protein (ICP4) of HSV-1 is associated with purified virions. Journal of Virology 633338–3344
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-73-4-811
Loading
/content/journal/jgv/10.1099/0022-1317-73-4-811
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error